News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: Investors Embrace Future Of Biologics Drugs In Samsung Biologics ' $2 Billion IPO



11/14/2016 9:58:33 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Samsung Biologics, a Korean biologics CMO/biosimilar company, completed a $2 billion IPO in South Korea at an $8 billion valuation; Qiming Venture closed its fourth RMB fund at $222 million; Beijing's BeiGene filed to raise as much as $150 million in a secondary offering for its novel oncology drug programs; Hangzhou's Betta Pharma raised $106 million via an IPO on Shenzhen's Chi-Next Exchange; Yisheng Biopharma, a Beijing vaccine company, will collaborate with San Diego's Scripps Research Institute to test its PIKA vaccine adjuvant; Genexine of Korea and Merck/MSD joined forces to develop a two-drug treatment for HPV-induced cancer; Shanghai's Eddingpharm signed a deal with Lilly China for two well-established Lilly antibiotics in China, and Eddingpharm also in-licensed China rights to an insomnia drug ZolpiMist® from Suda of Australia; Ping An Insurance has added 10,000 medical clinics in mainland China to its Wanjia Clinics chain since July; and Sirnaomics, a US-China pharma, reported approval of a US IND for a Phase II trial of its lead RNAi therapeutic.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES